ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer.
Interventions of Interest:
- Rucaparib (Rubraca®, Clovis Oncology)
- Niraparib (Zejula®, Tesaro, Inc.)
- Olaparib (Lynparza®, AstraZeneca)
University of Missouri-St. Louis
Century BC Room, Millenium Student Center
1 University Boulevard
St. Louis, MO 63121
The Midwest CEPAC convened to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.